Kuros Biosciences to provide investor update at Octavian and Baader Bank Conferences

Core Insights - Kuros Biosciences announced significant milestones including health system approvals, regulatory certifications, and preclinical evidence supporting the global expansion of MagnetOs, to be presented at upcoming investor conferences [2][3] Recent U.S. Healthcare System Approvals - All five formulations of MagnetOs have received approval from multiple large Integrated Delivery Network (IDN) health systems in the U.S., facilitating broader access and adoption [4] - These approvals are based on comprehensive evaluations by multidisciplinary teams assessing efficacy, safety, and economic considerations, which will enhance surgeon access to MagnetOs [5] Regulatory Achievements - MagnetOs Granules and MagnetOs Putty achieved certification under the European Union Medical Device Regulation (MDR) on December 22, 2025, ensuring continued market access in the EU [6][7] - MDR certification is recognized as one of the most stringent regulatory frameworks globally, reflecting the strength of Kuros' clinical evidence [8] Preclinical Study Publication - A newly published preclinical study demonstrated that MagnetOs Flex Matrix achieved significantly higher fusion rates compared to various synthetic bone grafts in a sheep model, with 100% bilateral fusion in MagnetOs treated segments [9][10] - This study emphasizes the importance of robust multi-endpoint analysis in distinguishing true bone fusion outcomes, further differentiating MagnetOs from competing technologies [10] Ongoing Clinical Development - Kuros is continuing its clinical development efforts with the ASTRA study, a global, prospective, randomized, controlled trial evaluating MagnetOs against autograft in patients undergoing hindfoot or ankle fusions [10] Upcoming Events - Key upcoming events include the Octavian Seminar on January 15, 2026, and the Baader Bank Swiss Equities Conference on January 16, 2026, where the company will provide further updates [11]